Page 23 - Read Online

Page 12 of 12 Ruff et al. Hepatoma Res 2023;9:17 https://dx.doi.org/10.20517/2394-5079.2023.18

54. Conci S, Viganò L, Ercolani G, et al. Outcomes of vascular resection associated with curative intent hepatectomy for intrahepatic
cholangiocarcinoma. Eur J Surg Oncol 2020;46:1727-33. DOI
55. Ali SM, Clark CJ, Zaydfudim VM, Que FG, Nagorney DM. Role of major vascular resection in patients with intrahepatic
cholangiocarcinoma. Ann Surg Oncol 2013;20:2023-8. DOI PubMed
56. Franssen S, Soares KC, Jolissaint JS, et al. Comparison of hepatic arterial infusion pump chemotherapy vs resection for patients with
multifocal intrahepatic cholangiocarcinoma. JAMA Surg 2022;157:590-6. DOI PubMed PMC
57. Wright GP, Perkins S, Jones H, et al. Surgical resection does not improve survival in multifocal intrahepatic cholangiocarcinoma: a
comparison of surgical resection with intra-arterial therapies. Ann Surg Oncol 2018;25:83-90. DOI
58. Cercek A, Boerner T, Tan BR, et al. Assessment of hepatic arterial infusion of floxuridine in combination with systemic gemcitabine
and oxaliplatin in patients with unresectable intrahepatic cholangiocarcinoma: a phase 2 clinical trial. JAMA Oncol 2020;6:60-7. DOI
PubMed PMC
59. Bekki Y, Von Ahrens D, Takahashi H, Schwartz M, Gunasekaran G. Recurrent intrahepatic cholangiocarcinoma - review. Front Oncol
2021;11:776863. DOI PubMed PMC
60. Zhang XF, Beal EW, Bagante F, et al. Early versus late recurrence of intrahepatic cholangiocarcinoma after resection with curative
intent. Br J Surg 2018;105:848-56. DOI
61. Hu LS, Zhang XF, Weiss M, et al. Recurrence patterns and timing courses following curative-intent resection for intrahepatic
cholangiocarcinoma. Ann Surg Oncol 2019;26:2549-57. DOI
62. Spolverato G, Kim Y, Alexandrescu S, et al. Management and outcomes of patients with recurrent intrahepatic cholangiocarcinoma
following previous curative-intent surgical resection. Ann Surg Oncol 2016;23:235-43. DOI
63. Bartsch F, Eberhard J, Rückert F, et al; German ICC Collaboration Group. Repeated resection for recurrent intrahepatic
cholangiocarcinoma: a retrospective German multicentre study. Liver Int 2021;41:180-91. DOI
64. Gani F, Nagarajan N, Kim Y, et al. Program death 1 immune checkpoint and tumor microenvironment: implications for patients with
intrahepatic cholangiocarcinoma. Ann Surg Oncol 2016;23:2610-7. DOI
65. Oh D, He AR, Qin S, et al. A phase 3 randomized, double-blind, placebo-controlled study of durvalumab in combination with
gemcitabine plus cisplatin (GemCis) in patients (pts) with advanced biliary tract cancer (BTC): TOPAZ-1. JCO 2022;40:378-378.
DOI
66. Zhu AX, Borger DR, Kim Y, et al. Genomic profiling of intrahepatic cholangiocarcinoma: refining prognosis and identifying
therapeutic targets. Ann Surg Oncol 2014;21:3827-34. DOI PubMed PMC
67. Chmiel P, Gęca K, Rawicz-Pruszyński K, Polkowski WP, Skórzewska M. FGFR inhibitors in cholangiocarcinoma-a novel yet primary
approach: where do we stand now and where to head next in targeting this axis? Cells 2022;11:3929. DOI PubMed PMC
68. Lowery MA, Ptashkin R, Jordan E, et al. Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas:
potential targets for intervention. Clin Cancer Res 2018;24:4154-61. DOI PubMed PMC
69. Javle MM, Abou-alfa GK, Macarulla T, et al. Efficacy of derazantinib in intrahepatic cholangiocarcinoma patients with FGFR2
mutations or amplifications: interim results from the phase 2 study FIDES-01. JCO 2022;40:427-427. DOI
70. Kim SH, Han DH, Choi GH, Choi JS, Kim KS. Extent of lymph node dissection for accurate staging in intrahepatic
cholangiocarcinoma. J Gastrointest Surg 2022;26:70-6. DOI PubMed